6861:TSE

InnoCare’s stock is trading well above its 20‑day (≈101), 50‑day (≈78) and 200‑day (≈61) simple moving averages, confirming a strong bullish momentum supported by a bullish MACD histogram (+5.2) and a stable volume profile. However, the RSI sits at an elevated 77.7, signaling short‑term over‑extension, while 30‑day volatility spikes at 88%, suggesting the price could swing sharply.
Fundamentally, the company commands a high price‑to‑earnings multiple of 42.9 versus an industry average of 25.4 and its discounted cash‑flow fair value is only about 101, far below the current price of 148.5, indicating the stock is materially overvalued. Nonetheless, revenue is growing at a solid 14.7% year‑over‑year, free cash flow remains positive, and a 1.33% dividend yield with a 52% payout ratio points to a sustainable income stream.
Risk factors include a high debt‑to‑equity ratio (~10x) that, despite ample cash on hand, raises leverage concerns, while the beta of ~0.7 implies limited market‑wide sensitivity. The medical‑device sector adds medium regulatory exposure, and Taiwan’s geopolitical environment introduces medium geographic risk, compounded by a relatively thin recent trading volume that may affect liquidity.